Test
340 articles
“Radical Collaboration” to Find Cures for the Deadliest Cancers
Break Through Cancer was founded to promote collaboration between major research institutions, in order to develop cures for the deadliest cancers.
New Study Targets Specific BRAF Mutation
One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian.
New Study Tackles the Link Between Sleep Disruption and Cachexia
Cachexia occurs frequently among pancreatic cancer patients. Dr. Evan Noch is looking at how sleep disruption and cachexia interact.
mRNA Pancreatic Cancer Vaccine Trial Heading for Phase II
Dr. Vinod Balachandran provides the latest data on the mRNA pancreatic cancer vaccine, now headed to a phase II clinical trial.
Chemo and SBRT for Inoperable Pancreatic Cancer
For inoperable pancreatic cancer, researchers are comparing mFOLFIRINOX and SBRT with gemcitabine-based treatment regimens.
Two-Year Survivor and Going Strong
Susan Hoopengarner coordinated her care between a local hospital and a major cancer center for chemotherapy and a Whipple procedure.
Going After a Specialized Radiation Treatment
Don Myrah wanted more than chemotherapy. He read about a specialized radiation treatment and directly contacted the company behind it.
LET’S WIN! PANCREATIC CANCER Turns 5!
Let’s Win has reached its 5th anniversary. Read about our development and what we have accomplished in 5 short years.
COVID-19: What You Should Do Now
Learn what you should do to prevent the spread of COVID-19, especially if you have a weakened immune system from pancreatic cancer treatment.
Let’s Win! Pancreatic Cancer Updates Clinical Trials Section
Let’s Win announces updates to its clinical trials section on its website. These include a new clinical trial finder, animations,and educational pages.
An Exemplary Life: The PR Lessons Anne Glauber Left Us
A tribute to the life, works, and pancreatic cancer treatment education mission of Anne Glauber, founder of Let’s Win, by Seth Arenstein.
Surveillance Improves Outcomes for High-Risk Patients
Dr. Michael Goggins provides results for the CAPS5 pancreatic cancer surveillance and screening study for patients at high risk.
New Clinical Accelerator Initiative Shortens Time from Bench to Clinic
Dr. Elizabeth Jaffee explains the importance of Lustgarten’s Clinical Accelerator Initiative to speed up the time from bench to trial.
Large Phase III Global Trial Targets Cancer Metabolism
Dr. Philip Philip focuses on disrupting cancer cell metabolism with devimistat, now in a phase III global clinical trial.
Reducing Pancreatic Cancer Risk Through Chemoprevention
Dr. Peter Allen leads a clinical trial of chemoprevention–the use of a medication to prevent IPMNs from developing into pancreatic cancer.